Abbott India Q2 FY27 Results: Standalone Net Profit ₹453 Crore on Total Income of ₹2,019 Crore
- Earnings
- Pharmaceuticals
Reviewed byKeshav SehgalBlacklitt Research
Abbott India (NSE: ABBOTINDIA) reported total income of ₹2,019.07 crore and net profit of ₹453.45 crore on a standalone basis for the quarter ended 30 Sep 2026, it said in a filing on 05 Nov 2026. The board approved the unaudited results on 5 Nov 2026.
Key highlights
Standalone
The company on its own, without its subsidiaries
- Total income: ₹2,019.07 crore, up 10.5% YoY and 6.9% QoQ
- Net profit and EPS: ₹453.45 crore, up 9.2% YoY; basic EPS ₹213.39
- Profit before tax: ₹610.47 crore, up 11.8% YoY and 6.7% QoQ
- Dividend paid, six months: ₹1,393.95 crore in the cash flow statement
Summary
| Particulars | Q2 FY27 | Q2 FY26 | YoY | Q1 FY27 | QoQ |
|---|---|---|---|---|---|
| 2,019.07 | 1,827.10 | +10.5% | 1,889.05 | +6.9% | |
| Revenue from operations | 1,951.01 | 1,757.15 | +11.0% | 1,813.68 | +7.6% |
| Other income | 68.06 | 69.95 | -2.7% | 75.37 | -9.7% |
| 453.45 | 415.27 | +9.2% | 428.52 | +5.8% | |
| Profit before tax | 610.47 | 545.93 | +11.8% | 572.21 | +6.7% |
| Finance costs | 5.95 | 7.55 | -21.2% | 5.91 | +0.7% |
| Depreciation | 19.49 | 18.64 | +4.6% | 19.75 | -1.3% |
| Tax expense | 157.02 | 130.66 | +20.2% | 143.69 | +9.3% |
| Net profit margin | 22.46% | 22.73% | -0.27 pp | 22.68% | -0.23 pp |
| EPS, basic (₹) | 213.39 | 195.42 | +9.2% | 201.66 | +5.8% |
Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.
Net profit grew more slowly than income. Total income rose 10.5% year on year to ₹2,019.07 crore, while net profit rose 9.2% to ₹453.45 crore. Profit before tax grew 11.8%, so the tax expense, up 20.2% to ₹157.02 crore, took a larger share of the increase.
Revenue from operations rose 11.0% to ₹1,951.01 crore, and other income fell 2.7% to ₹68.06 crore. Other income is 3.4% of total income and 11.1% of profit before tax. Finance costs were ₹5.95 crore, or 0.3% of total income, down from ₹7.55 crore a year earlier.
The tax expense is 25.7% of profit before tax this quarter. The statement shows a tax adjustment for earlier years of ₹(6.04) crore and a deferred tax credit of ₹(1.00) crore in the quarter ended 30 Sep 2025, the year-earlier comparison period.
The auditor, Walker Chandiok & Co LLP, conducted a limited review and the review report contains no qualifications. The company has one segment, Pharmaceuticals, and results are prepared under Ind AS 34.
Inference
For the six months ended 30 Sep 2026, the filing reports total income of ₹3,908.12 crore, profit of ₹881.97 crore and basic EPS of ₹415.04, not annualised. Other equity stood at ₹4,248.95 crore and total assets at ₹5,924.91 crore on the same date.
The filing does not state whether a dividend has been declared for the period or its record date, and it does not explain the reason for the rise in other financial assets as at 30 Sep 2026.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
